BCBS North Dakota

Does BCBS North Dakota cover Wegovy?

Quick answer · Weight Loss

BCBS North Dakota covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher
  • ACA Marketplace: Covered with requirements. BMI of 30 or higher

Last verified June 2, 2026. Policy effective April 20, 2026. Source: ND_Weight_Management_PAQL_ProgSum.pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What BCBS North Dakota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, and CVD)
  • BMI of 25 or higher for patients of Asian descent
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult obesity without comorbidity

All of:

  • BMI >= 30 kg/m2 (or >= 25 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Adult overweight with comorbidity

All of:

  • BMI >= 27 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Plus any one of:

  • Hypertension
  • Type 2 diabetes
  • Dyslipidemia
  • Obstructive sleep apnea
  • Cardiovascular disease
  • Other weight-related comorbid condition

Pediatric (age >= 12) obesity

All of:

  • Age >= 12 years
  • Body weight > 60 kg
  • Obesity diagnosis

Documentation to bring

  • Documentation of BMI >= 30 kg/m2 or >= 27 kg/m2 with at least one weight-related comorbidity
  • Documentation of prior comprehensive lifestyle intervention program attempt or reason it is not feasible
  • Documentation of weight-related comorbid condition if BMI is 27-29.9 kg/m2

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight, Per referenced guidelines, if weight loss >= 5% of body weight at 3 months, medication should be continued. If weight loss < 5% at 3 months or safety/tolerability issues, medication should be discontinued, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: Document is a program summary with clinical rationale referencing AHA/ACC/Obesity Society 2013 guidelines, AACE/ACE guidelines, Endocrine Society guidelines, and AGA 2022 guidelines. Full PA criteria details (specific approval criteria, quantity limits) are not fully enumerated in the provided document text. Asian BMI threshold of 23 kg/m2 referenced in AACE guidelines cited within the document for South Asian, Southeast Asian, and East Asian adults. Wegovy is available as both subcutaneous injection and tablet formulations per FDA indications listed. Pediatric indication applies to ages >= 12 with body weight > 60 kg.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, and CVD)
  • BMI of 25 or higher for patients of Asian descent
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult obesity without comorbidity

All of:

  • BMI >= 30 kg/m2 (or >= 25 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Adult overweight with comorbidity

All of:

  • BMI >= 27 kg/m2 (or >= 23 kg/m2 for South Asian, Southeast Asian, or East Asian adults)
  • Inadequate response to comprehensive lifestyle intervention program

Plus any one of:

  • Hypertension
  • Type 2 diabetes
  • Dyslipidemia
  • Obstructive sleep apnea
  • Cardiovascular disease
  • Other weight-related comorbid condition

Pediatric (age >= 12) obesity

All of:

  • Age >= 12 years
  • Body weight > 60 kg
  • Obesity diagnosis

Documentation to bring

  • Documentation of BMI >= 30 kg/m2 or >= 27 kg/m2 with at least one weight-related comorbidity
  • Documentation of prior comprehensive lifestyle intervention program attempt or reason it is not feasible
  • Documentation of weight-related comorbid condition if BMI is 27-29.9 kg/m2

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight, Per referenced guidelines, if weight loss >= 5% of body weight at 3 months, medication should be continued. If weight loss < 5% at 3 months or safety/tolerability issues, medication should be discontinued, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: Document is a program summary with clinical rationale referencing AHA/ACC/Obesity Society 2013 guidelines, AACE/ACE guidelines, Endocrine Society guidelines, and AGA 2022 guidelines. Full PA criteria details (specific approval criteria, quantity limits) are not fully enumerated in the provided document text. Asian BMI threshold of 23 kg/m2 referenced in AACE guidelines cited within the document for South Asian, Southeast Asian, and East Asian adults. Wegovy is available as both subcutaneous injection and tablet formulations per FDA indications listed. Pediatric indication applies to ages >= 12 with body weight > 60 kg.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

Wegovy for Heart Disease Risk Reduction

What BCBS North Dakota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition
  • Established cardiovascular disease (CV death, nonfatal MI, and nonfatal stroke)

Qualification pathways

You can qualify through any one of these.

CV risk reduction in adults with established CV disease and obesity or overweight

All of:

  • Adult patient (age >= 18)
  • Established cardiovascular disease
  • Obesity (BMI >= 30) or overweight (BMI >= 27)

Documentation to bring

  • Documentation of established cardiovascular disease
  • Documentation of BMI >= 27 kg/m2 (overweight or obese)

Not covered when

  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: FDA indication listed in document for CV risk reduction: to reduce the risk of major adverse CV events (CV death, non-fatal MI, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. Available as both tablet and subcutaneous injection formulations. Full PA criteria beyond FDA indication summary not enumerated in provided document text.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition
  • Established cardiovascular disease (CV death, nonfatal MI, and nonfatal stroke)

Qualification pathways

You can qualify through any one of these.

CV risk reduction in adults with established CV disease and obesity or overweight

All of:

  • Adult patient (age >= 18)
  • Established cardiovascular disease
  • Obesity (BMI >= 30) or overweight (BMI >= 27)

Documentation to bring

  • Documentation of established cardiovascular disease
  • Documentation of BMI >= 27 kg/m2 (overweight or obese)

Not covered when

  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: FDA indication listed in document for CV risk reduction: to reduce the risk of major adverse CV events (CV death, non-fatal MI, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. Available as both tablet and subcutaneous injection formulations. Full PA criteria beyond FDA indication summary not enumerated in provided document text.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

Wegovy for Liver Disease (MASH)

What BCBS North Dakota requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Confirmed MASH diagnosis, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with moderate to advanced liver fibrosis

All of:

  • Adult patient (age >= 18)
  • Diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
  • Moderate to advanced liver fibrosis consistent with stages F2 to F3

Documentation to bring

  • Documentation of noncirrhotic MASH diagnosis
  • Documentation of liver fibrosis stage F2 to F3 (moderate to advanced fibrosis)

Not covered when

  • Cirrhotic MASH is excluded (noncirrhotic only)
  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: FDA indication for MASH listed as subcutaneous injection formulation only (not tablet). Indication is for noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3). Specific confirmation methods, lookback periods, and alcohol use requirements are not enumerated in the provided document text — only the FDA indication summary is presented.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Confirmed MASH diagnosis, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with moderate to advanced liver fibrosis

All of:

  • Adult patient (age >= 18)
  • Diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
  • Moderate to advanced liver fibrosis consistent with stages F2 to F3

Documentation to bring

  • Documentation of noncirrhotic MASH diagnosis
  • Documentation of liver fibrosis stage F2 to F3 (moderate to advanced fibrosis)

Not covered when

  • Cirrhotic MASH is excluded (noncirrhotic only)
  • Coadministration with other semaglutide-containing products is not recommended
  • Coadministration with any other GLP-1 receptor agonist is not recommended

Policy note: FDA indication for MASH listed as subcutaneous injection formulation only (not tablet). Indication is for noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3). Specific confirmation methods, lookback periods, and alcohol use requirements are not enumerated in the provided document text — only the FDA indication summary is presented.

Policy effective April 20, 2026 · verified June 2, 2026 · source: ND_Weight_Management_PAQL_ProgSum.pdf

Why Wegovy requests get denied by BCBS North Dakota

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does BCBS North Dakota cover Wegovy?
BCBS North Dakota covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Wegovy under BCBS North Dakota?
For weight loss on Employer / Commercial Insurance plans, BCBS North Dakota requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
What does BCBS North Dakota require to renew Wegovy?
At least 5% weight loss from the starting weight, Per referenced guidelines, if weight loss >= 5% of body weight at 3 months, medication should be continued. If weight loss < 5% at 3 months or safety/tolerability issues, medication should be discontinued, and at least 12 weeks on therapy before the first renewal.
How current is this information?
This page reflects BCBS North Dakota's written policy as of April 20, 2026, last verified against the source document on June 2, 2026.

Other medications under BCBS North Dakota

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes BCBS North Dakota's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.